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Iridium complex, a promising organic light-emitting diode for next generation televisiom 
display, emits phosphorescence. Phosphorescence is quenched by oxygen. We used this 
oxygen-quenching feature for imaging tumor hypoxia. Red light-emitting iridium 
complex Ir(btp)2(acac) (BTP) presented hypoxia-dependent light emission in culture cell 
lines, whose intensity was in parallel with HIF-1α expression. BTP was further applied to 
imaging five tumors (four from human origin and one from mouse origin) transplanted 
in athymic mice. All tumors presented a bright BTP-emitting image even 5 min after the 
injection. The BTP-dependent tumor image peaked at 1 to 2 h after the injection, and 
was then cleared off from tumors within 24 h. The minimal BTP image recognition size 
was 3 to 4 mm in diameter. Compared with 18F-FDG/PET images, BTP delineated a 
clearer image for a tumor profile. We suggest that iridium complex has a vast potential 
for imaging hypoxic lesions such as tumor tissues. (150 words) 
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An organic light-emitting diode (OLED) is a promising device for thinner, lighter, and 
higher-resolution displays for next generation televisions, computers, electronic books, and 
billboards (1,2). As a low voltage-powered OLED emitter, Tang and VanSlyke introduced 
tris(8-hydroxyquinolinato)aluminum (Alq3) to an organic thin film device (3).  In 1990 
Friend and colleagues incorporated another device, a conducting polymer 
poly(p-phenylenevinylene), as an OLED emitter. Since then, enormous progress has been 
made towards the advancement of OLED emitter technology (1,2). These Alq3 and their 
derivative devices and conducting polymers emit fluorescence, whose electroluminescence 
efficiency (quantum yield) is limited to 25% at maximum. In contrast to fluorescent OLED 
devices, a new type of organometallic phosphorescent OLEDs was introduced around the turn 
to the new century (4). Such a highly attractive OLED is exemplified by iridium complex, 
Ir(btp)2(acac) (BTP; bis(2-(2’-benzothienyl)-pyridinato-N,C3’)iridium(acetylacetonate) (5). 
Phosphorescence is superior to fluorescence in terms of its internal quantum yield. 
Fluorescence emits light from singlet states whose spin statistics are predicted at a maximum 
25% of charge recombinations while spin statistics of phosphorescence start from triplet states, 
thus the upper limit of the internal quantum yield increases from 25% to nearly 100% (2). 
Furthermore, phosphorescence exhibits another conspicuous feature, oxygen quenching, by 
which iridium complex devices have to be shielded from the exposure to oxygen. This 
property suggests that the iridium complex devices emit phosphorescence, depending 
inversely on oxygen concentrations. 
Hypoxia is highly notable in tumor tissues (6,7), where hypoxia-inducible factor 
(HIF)-1α is induced by inhibiting its degradation through the decrease in oxygen-sensing 
prolyl 4-hydroxylase activity (8,9). HIF-1α regulates a variety of gene expressions including 
vascular endothelial growth factor (VEGF), erythropoietin, and glucose transporter (Glut)-1. 
Through HIF-1α-mediated gene expression, tumors are vascularized by VEGF to receive 
oxygen and nutrients for their growth in a hypoxic milieu (7). Several hypoxia-associated 
probes have been developed for tumor imaging including nitroimidazole (10,11), 
Cu-diacetyl-bis(N4-methylthiosemicarbazone (Cu-ATSM) (12), and fluorodeoxyglucose 
(FDG) (13). Nitroimidazole and Cu-ATSM are thought to bind to macromolecules in a 
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hypoxia-induced redox state-dependent manner. FDG is extensively taken up into tumor cells 
through glucose transporter 1 (Glut1), which is up-regulated by HIF-1α (7,13). They are used 
with radioisotope labeling for visualization by positron emission tomography (PET).  
An optical method was demonstrated to directly detect oxygen in cells and tissues by 
using oxygen-dependent quenching of phosphorescence to visualize oxygen distribution in 
vivo (14). For this purpose, several kinds of phosphorescent probes such as metalloporphyrins 
and ruthenium(II) complexes have been developed (15,16). Since the phosphorescence of 
these organic compounds was extremely weak owing to their spin-forbidden nature even under 
a deaerated condition, heavy metal was placed in the center to induce the active mixing effect 
of the spin state on the π-electronic system of the ligands for enhancement of phosphorescence 
intensity. Phosphorescent oxygen probes have been developed by decorating “molecular 
coats” to oxygen-sensitive heavy metal complexes (15,17.18). The molecular coats protect the 
phosphor from the environment and give them hydrophilic nature, but their molecular size 
enlarges to over 2000 Da exemplified by the paradium-porphyrin complex (15). These 
phosphorescent probes have been applied to measure oxygen pressure in microcapillary 
vessels because these probes cannot penetrate into the plasma membrane due to their size and 
hydrophilic nature (15,17,19).  
Compared with the first stage phosphorescence probes, iridium complexes possess 
highly phosphorescent and photostable properties which are required for use of OLED 
emitters. Furthermore, we are able to employ various kinds of ligands to improve the 
photophysical and chemical properties (absorption and emission wavelengths, solubility, 
toxicity, etc.) for achieving optimal properties suitable to image hypoxic tissues. In this study, 
we employed the well-known red-emitting iridium complex Ir(btp)2(acac) (BTP) (Fig. 1a) as a 
phosphorescent probe. The red phosphorescence of BTP is advantageous for tissue penetrance, 
and its moderately long lifetime (5.8 μs in deaerated 1,2-dichloroethane) is favorable for 
oxygen-induced quenching. Based on these reasons, we applied this phosphorescent probe for 
hypoxic tumor imaging to test its feasibility. 
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RESULTS 
Photophysical properties of BTP complexes 
Since the chemical structure of BTP appears lipophilic (Fig. 1a), we examined its uptake into 
an artificial membrane composed of dimyristoyl-L-α-phosphatidylcholine (DMPC, 1 mM). 
Indeed, over 98% of BTP was partitioned into the membrane when BTP (10 μM) was 
dissolved in Tris-HCl buffer at 35°C. We then investigated the photophysical properties of 
BTP in DMPC liposome as well as in 1,2-dichloroethane and n-hexane solutions. BTP in a 
deaerated 1,2-dichloroethane solution showed the first absorption maximum at 483 nm with a 
molar absorption coefficient of 6,100 M-1cm-1, and showed intense phosphorescence from a 
ligand-centered ππ*state (promotion of a π-electron to an antibonding π* orbital) with 
significant admixtures of metal-to-ligand charge transfer (electron promotions from 
metal-centered to ligand-centered orbitals) character at 616 nm (Fig. 1b). The 
phosphorescence quantum yield ( 0pΦ ) and lifetime (τp
0) in a deaerated 1,2-dichloroethane 
solution (pO2 is assumed to be 0) were 0.32 and 5.8 μs, respectively, at room temperature. The 
phosphorescence quenching due to dissolved oxygen in solution or membrane can be obtained 
by the following Stern-Volmer equation: 
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where Φp and τp, respectively, are the phosphorescence quantum yield and phosphorescence 
lifetime at an oxygen partial pressure pO2, and kq is a bimolecular quenching rate constant (20). 
At 35°C, the kq value in n-hexane was determined to be 5.7 x 104 mmHg-1s-1 
(mmHg=millimeters of mercury) and that in DMPC membrane in Tris-HCl buffer (pH=7.0) 
was 1.2 x 104 mmHg-1s-1.  When τp0 = 5.3 μs (τp0 in DMPC membrane) and tissue pO2 = 60 
mmHg are applied to this equation and assuming that the quenching rate constants in the 
membrane and tissue are equal, p
0
p ΦΦ  comes to 4.8, indicating that BTP phosphorescence 
will be quenched in the tissue pO2 milieu of 60 mmHg. Since pO2 = 60 mmHg is not hypoxic 
as a tissue pO2 (7), BTP is presumed to become phosphorescent at lower pO2 than 60 mmHg, 
so it appears to be applicable to hypoxic tissue pO2 estimation. 
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Iridium complex BTP to culture cells in a hypoxic milieu 
Since the oxygen quenching feature of BTP appeared to be regulated in a physiological tissue 
pO2 milieu by the photophysical evaluation, we examined the oxygen quenching using culture 
cell lines. Three cell lines, human uterine cancer-derived HeLa, Chinese hamster 
ovary-derived CHO, and human glioma-derived U251, were placed in a 5% O2 culture 
condition. In normoxia, the three cell lines did not exhibit notable phosphorescence when 
loaded with BTP (50 μM) (Fig. 2a). In contrast, the three cell lines emitted bright red 
phosphorescence in a 5% O2 culture (Fig. 2a). We then observed the phosphorescence of BTP 
in decreasing O2 levels from 20% to 2.5% using HeLa cells (Fig. 2b, upper panel). With a 
decrease in O2 concentration, the phosphorescence increased in an inverted manner. Likewise, 
HIF-1α was increasingly immunostained with a decrease in O2 levels (Fig. 2b, lower panel). 
In accordance with this, HIF-1α protein gradually displayed an intensive band with the 
increasing intensity of phosphorescence (Fig. 2c). Since we observed the BTP 
phosphorescence emission in a hypoxia-dependent manner, we tested this probe to image 
tumors transplanted in athymic nude mice.  
 
BTP to tumor-bearing nude mice 
We used five culture cell lines for transplantation; human oral squamous carcinoma-derived 
SCC-7, human glioma-derived U87, human lymphoma-derived RAMOS, human colon 
carcinoma-derived HT-29, and mouse lung cancer-derived LL-2. Tumor size varied from 10 to 
15 mm. The histopathological features of each tumor were examined as follows: SCC-7, 
poorly differentiated carcinoma without any keratinization; U87, spindle-shaped glial cells 
with marked atypia; RAMOS, medullary growth of large atypical lymphocytes; HT-29, poorly 
differentiated adenocarcinoma cells forming tubular structures; and LL-2, poorly differentiated 
adenocarcinoma cells with intracytoplasmic vacuoles (Supplementary Fig. 1). Tumors grown 
from culture cells tended to show undifferentiated features. We then measured pO2 by an 
oxygen monitoring probe, and found that median pO2 ranged from 18 to 21 mmHg (Table 1). 
Thus, the pO2 of each tumor was lower than that of end-capillary blood whose pO2 ranges 
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from 45 to 50 mmHg (7). However, since Höckel and Vaupel stated that the critical pO2 below 
8-10 mmHg is associated with detrimental hypoxic changes such as decrease in cellular ATP 
levels (8), the pO2 levels in the five tumors appear to come under the moderate hypoxia 
criteria. To examine the expression of HIF-1α, we immunostained HIF-1α in the five tumors. 
HIF-1α was well stained in SCC-7 and HT-29 tumors, but was not well notable in the other 
tumors (Supplementary Fig. 1).  
 We dissolved BTP in dimethylsulfoxide (DMSO) because it was lipophilic. The BTP 
dose was determined using SCC-7 tumor-bearing mice by injecting 25 nmol, 125 nmol, 250 
nmol, and 500 nmol/mouse, and 250 and 500 nmol BTP/mouse was found to clearly depict a 
tumor image (Supplementary Fig. 2). BTP (250 nmol/100 μl DMSO) was injected from the 
tail vein under pentobarbital anesthesia. Each tumor-bearing mouse was placed in a dark box 
of the Maestro In-Vivo imaging System. Luminescence was detected 5 min after the injection 
in all five tumors, and it increased gradually to a 1 h-point (Fig. 3a). The shape and position of 
the luminescence spectra emitted from the tumors were identical with those of the 
phosphorescence spectrum of BTP shown in Fig. 1b, suggesting that BTP chemical structure 
was maintained in a spectrum basis (data not shown). Extra-tumor regions are generally 
non-luminescent, but when anesthesia is overdosed, the forearm, peri-oral and peri-nasal 
regions began to turn red.  
 We then determined the fate of BTP using SCC-7 tumors in athymic nude mice. The 
intensity of BTP was highest at 2 h after the injection, then declined gradually towards the 
24-h point, when the tumor was not imaged (Fig. 3b). We measured the pO2 level before and 
periodically after the BTP administration, and found that pO2 levels are not affected by BTP 
administration even after the peak of BTP phosphorescence (data not shown).  
 
Detection limit of tumor size and imaging depth 
We examined the detection limit of BTP-imaged tumor size. SCC-7 cells were injected into 
athymic nude mice and their tumor size was monitored daily. When the tumor reached 2 mm 
and more in diameter, we began to assess BTP imaging. When a tumor grew to 4 mm in 
diameter, its BTP-imaging was reliably detected (Fig. 4).  
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 One of the drawbacks of luminescent imaging is the penetration limit of luminescence. 
Although a red to near-infrared wavelength (>630 nm) is preferable for tissue penetration both 
in excitation and emission, the excitation wavelength of BTP is 483 nm at maximum although 
its emission is 616 nm at its first peak and 680 nm at its second peak (Fig. 1b). We measured 
the detection limit of BTP-imaging by placing a 1.2 mm slice of beef meat on a BTP gel 
composed of polyacrylamide. We could detect the BTP-imaging at a depth of 4.8 mm by 20 
nmol BTP and 7.2 mm by 200 nmol BTP, but it was more difficult to detect a depth of 8.4 mm 
from the surface (Supplementary Fig. 3). Thus, to obtain much deeper tissue penetration, 
BTP should be modified for excitation by a red to near-infrared wavelength. 
 
Comparison of BTP-imaging with 18F-FDG-imaging 
The BTP image depicted tumor profiles almost accurately in each tumor. Since FDG-PET is 
routinely used for screening dormant tumors in medicine, we compared the BTP-imaging with 
FDG-PET imaging. We selected similar size tumors grown on the right pelvic region, one for 
BTP-imaging and the other for 18F-FDG-imaging. The BTP image was limited to tumor 
profiles in each tumor, whereas the 18F-FDG-image looked vague in all five mice. We could 
barely find a limited image in the U87MG, and HT-29 tumors (Supplementary Fig. 4). Apart 
from tumor-imaging, the 18F-FDG-image was distributed to non-tumor tissues such as the 
brain and the heart, and resulted in widely spreading images in each mouse. Thus, we suggest 
that BTP-image is much clearer than 18F-FDG-image.  
 
Toxicity 
As the first step for evaluating BTP toxicity, we examined cell viability using HeLa cells by 
trypan blue dye-exclusion assay and apoptosis by staining with Hoechst 33342 DNA binding 
dyes plus propidium iodide fluorescence. We used cholesterol as a negative control and 
7-ketocholesterol as a positive control because both are lipophilic similar to BTP (21). Both 
cell viability and apoptosis by BTP were similar to those in the cholesterol control 
(Supplementary Fig. 5). 
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DISCUSSION 
We demonstrated a promising potential of phosphorescent OLED, iridium complex, for tumor 
imaging. To visualize hypoxic tissues, phosphorescence is superior to fluorescence because of 
one of its specific features, oxygen quenching. Using this feature, phosphorescent probes such 
as BTP can be visualized in a hypoxic milieu such as tumors. Tumors were visible even 5 min 
after the BTP injection (Figs. 3a). The luminescent region became widespread over the tumor 
profile 1 to 2 h after the BTP injection, and disappeared within 24 h (Fig. 3b). In a 
tumor-bearing mouse, BTP is distributed systemically to its whole body, and emits 
phosphorescence where oxygen supply is insufficient. In this sense, iridium complex is 
distinct in its luminescence emission in comparison to other tumor-detecting probes, such as 
nitroimidazole, Cu(II)-ATSM, and 18F-FDG. In other words, iridium complex is a 
hypoxia-sensing emitter, while the above three are a hypoxia-accumulating emitter. For 
example, nitroimidazole accumulates in a hypoxic tissue where the nitro residues are reduced 
by the lack of sufficient oxygen, and a reduced form of nitroimidazole is thought to bind to 
macromolecules (11,22). Nitroimidazole has been developed for use with a 
radioisotope-labeled PET probe, such as [18F]-fluoromisonidazole (FMISO) (23) and 
[18F]-fluoroetanidazole (24). Cu(II)-ATSM is also reduced in hypoxic tissue to release Cu(I), 
which is thought to bind to macromolecules. Thus, when Cu is radiolabeled as 60Cu, 61Cu, 
62Cu, or 64Cu, radiolabeled Cu is trapped in the hypoxic tissue (25). These probes should be 
radiolabeled for PET and requires cost-taking PET facilities and equipments. 
 Recently, quantum dots (QDs) have attracted much attention as a fluorescent probe 
for tumor imaging, although tumor imaging mechanisms of QDs do not depend on hypoxia 
(26,27). But tumor vasculature has large penetration gaps for macromolecules such as 
nanometer-size QD particles. Furthermore, QD has been extensively modified by decorating a 
variety of molecules for better trapping to tumor tissues (28,29). QDs are made of CdSe-ZnS 
in their core shell (27). Thus, QDs are used for shielding with a safe lining because Cd is toxic 
(30). Although QDs may be safe in the body, excreted QDs from animals, and animals 
retained with QDs have to be disposed safely. Thus, the toxicity problem of QDs has not been 
settled yet (30,31). On the other hand, iridium complex appears to be safe based on a 
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preliminary toxicity experiment (Supplementary Fig. 5). We also noted that mice were 
healthy for over three months after a high dose injection of BTP (data not shown).  
 18F-FDG is most frequently used for PET as a probe for tumor imaging (32). FDG is 
taken up to cells through Glut1, and its retention to tumors depends on the balance between 
hexokinase and glucose-6-phosphatase (G6Pase) activities (13). In a hypoxic condition, Glut1 
is induced by HIF-1α for increasing uptake of glucose (8-10). FDG is phosphorylated to 
FDG-6-P by hexokinase, but FDG-6-P cannot be converted further to fluorodeoxyfructose 
6-phosphate by phosphohexose isomerase because hydroxyl residue at position 2 is replaced 
by fluorine. Conversely, FDG-6-P can be reversed to FDG by G6Pase if G6Pase activity is 
high, and as a result, FDG may be removed out from the cell. Since tumors such as early 
prostate cancer and well-differentiated hepatoma have high G6Pase activity, FDG/PET is not 
adequate for the detection of these tumors (13). In this study, FDG/PET did not depict a clear 
tumor image in all five tumors compared with BTP-imaged tumors (Supplementary Fig. 4).  
FDG/PET resulted in bright images in non-tumor-residing regions, perhaps reflecting an 
FDG-incorporating brain, heart, and muscle images in all mice. Further, FDG/PET imaging 
barely delineates a tumor profile. Thus, the BTP image looks much better in depicting a tumor 
profile than FDG image.  
 But luminescent probes have an inevitable drawback, that is, their weak tissue 
penetration capacity, which is reportedly about 1 cm deep even when near-infrared 
wavelength light was used (26). The phosphorescence of BTP appears in the red to 
near-infrared region (>615nm), while the excitation wavelength is limited to the visible light 
region (445-490nm). Indeed, when we placed a mouse with the tumor underneath, we could 
not detect the BTP-imaged tumor profile perhaps due to its approximately 3 cm-thick body. 
To determine a depth-dependent detection limit, we placed a 1.2 mm slice of pork meat on a 
BTP polyacrylamide gel (20 nmole and 200 nmole of BTP/200 μl gel), and could detect 
phosphorescence approximately 5-7 mm deep from the surface depending on the BTP dosage 
(Supplementary Fig. 3). We further improved BTP by adding phenyl residues (BTQ) thus 
making the excitation wavelength shift 540 nm longer. But the penetration limit stayed in a 
similar range to that of BTP (data not shown). Thus, BTP imaging is preferable when tumors 
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are situated close to the tissue surface. In this sense, we suggest that BTP imaging may be a 
promising technique for the detection of gastrointestinal tumors involving mucosal to 
submucosal layers with use of an endoscope. Since the detection limit of tumor size was 
estimated to be approximately 4 mm in diameter (Fig. 4), microadenoma and microcancer 
appear to be a target of BTP imaging. We suggest that iridium complex has practical 
feasibility for tumor hypoxia imaging, and it will have a promising potential for a 
hypoxia-indicating chemical probe in assistance with other imaging techniques such as PET 
scanning and endocytoscopy. 
 
 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
07
.1
44
3.
1 
: P
os
te
d 
19
 D
ec
 2
00
7
  Zhang et al./First submission 
 -12- 
METHODS 
Physicochemical features of iridium complex.  BTP was synthesized according to the 
previous literature (5). A mixture of 2-(benzo[b]thiophen-2-yl)pyridine (460 mg, 2.2 mmol), 
IrCl3•3H2O (390 mg, 1 mmol), 2-ethoxyethanol (30 ml), and distilled water (10 ml) was 
heated at reflux for 15 h. After cooling, the precipitate formed was filtered to give a 
chloro-bridged dimer and washed thoroughly with methanol and n-hexane. To the mixture of 
the chloro-bridged dimer (260 mg, 0.2 mmol) and Na2CO3 (170 mg, 1.6 mmol), 
2-methoxyethanol (30 ml) and acetyl acetone (1.0 ml, 9.5 mmol) were added, and then the 
slurry was refluxed for 2h. After the mixture was cooled down, the precipitate formed was 
collected by filtration and washed thoroughly with methanol and n-hexane. Yield: 180 mg 
(62 %). 1H NMR (300 MHz, CDCl3) δ : 8.43 (d, 2H, J = 5.4 Hz), 7.77 (t, 2H, J = 8.4 Hz), 7.63 
(d, 4H, J = 7.2 Hz), 7.07-6.99 (m, 4H), 6.80 (t, 2H, J = 7.8), 6.20 (d, 2H, J = 8.1 Hz), 5.26 (s, 
1H), 1.78 (s, 6H). 
Dimyristoyl-L-α-phosphatidylcholine (DMPC; Sigma 99%) was used for lipid 
membrane and liposome preparation. 1,2-Dichloroethane (DCE; Kishida, spectroscopic grade) 
was used without further purification. Deionized water was purified by using a Millipore 
(MILLI-Q-LABO). Small unilamellar vesicles were prepared by ethanol injection method. 
The ethanolic solution of DMPC (3.0 x 10-2 moldm-3, 0.1 ml) was injected rapidly into 
Tris/HCl buffer (2.85 ml, pH=7.0) at 50°C. The incorporation of BTP to the small unilamellar 
liposome vesicles was carried out by adding a stock solution of BTP (6.0 x 10-4 moldm-3, 0.05 
ml) in DMSO.  The final concentration of the BTP probe was 1.0 x 10-5 moldm-3. The 
solution was equilibrated for 1 h above the phase transition temperature (23°C) of DMPC. 
Absorption and emission spectra were measured with an UV/vis spectrophotometer 
(Jasco, Ubest-V550) and a spectrofluorimeter (Hitachi, F-4010), respectively. The emission 
spectrum was corrected for spectral sensitivity. 
 
Cell culture and BTP uptake. We used three cell lines, human uterine cancer-derived HeLa, 
Chinese hamster ovary-derived CHO, and human glioma-derived U251. We also used O2 
concentration-changeable multi-gas incubator MCO-5M (Sanyo, Osaka, Japan). Cells were 
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cultured in Dulbecco's modified Eagle's medium (DMEM, Invitrogen) containing 25 mmol/l 
glucose with 10% fetal bovine serum at 37°C. The O2 concentration was changed from 20% to 
10, 5.0, to 2.5%. The cells were cultured under four O2 concentrations, 2.5 %, 5 %, 10%, or 
20 % for 24 h at 37°C. Then, BTP was added to the medium at a final concentration of 50 µM 
for 1 h for visualization (535 nm excitation/580 nm emission). 
 
Tumor transplantation to nude mice. We conducted our animal experiments in accordance 
with the guidelines for the Care and Use of Laboratory Animals of the Medical Research 
Council of Gunma University. Tumor transplants were established in female athymic nude 
mice by injection of 1 x 107 human oral squamous carcioma-derived SCC-9, human 
glioma-derived U87, human lymphoma-derived RAMOS, human colon carcinoma-derived 
HT-29, and mouse lung cancer-derived LL-2. Experiments with tumor-bearing mice were 
performed two weeks after injection of tumor cells. 
 
Immunostaining and immunoblot. Tumors were quickly removed, and fixed with 4% 
paraformaldehyde/0.1M phosphate buffer. Histological sections from cryostat blocks were 
stained with hematoxylin and eosin (HE). For HIF-1α immunostaining, cryostat specimens or 
fixed cells were stained with a mouse monoclonal antibody to HIF-1α (dilution 1:200, 
Sigma-Aldrich), then with a second immunostaining with the Labelled Streptavidin-Biotin2 
System with horseradish peroxidase (LSAB2 System, Dako). 
The expressions of HIF-1α were measured by immunoblotting. HeLa cells were lysed 
in a lysis buffer [50 mM HEPES (pH 7.0), 250 mM NaCl, 0.1% Nonidet P-40, 100 mM NaF, 
0.2 mM sodium orthovanadate, 0.5 mM phenylmethylsulfonyl fluoride, 10 μg/ml aprotinin, 10 
μg/ml leupeptin, and 10 μg/ml pepstatin]. Cell lysates (15 μg protein/lane) were separated on a 
SDS-PAGE for nitrocellulose membrane blotting. The blotted membranes were incubated with 
the antibody to HIF-1α.  
 
In vivo imaging. Luminiscence images of a whole mouse body and close-up image were 
obtained using the Maestro FL500 in vivo imaging system (CRi, Inc., Woburn, MA). A 
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band-pass filter from 445 to 490 nm and a long-pass filter over 515 nm were used for 
excitation and emission light, respectively. The tunable filter was automatically stepped in 
10-nm increments from 550 to 800 nm while the camera captured images at each wavelength 
interval with 1500 ms exposure. The spectral fluorescence images consisting of 
auto-fluorescence spectra and BTP spectra were obtained and then unmixed, based on their 
spectral patterns using commercial software (Maestro software, CRi, Inc.). The spectra for 
unmixed image are shown in Fig. 3 (Blue and sky-blue are auto-fluorescence; Red is BTP 
spectra). For BTQ imaging, a band-pass filter from 503 to 555 nm and a long-pass filter over 
580 nm were used for excitation and emission light. 
 
Measurement of oxygen partial pressure. Oxygen partial pressure (pO2) in the tumors was 
measured with a needle-type polarographic oxygen electrode (PO2-150S, Eikou-kagaku Co. 
Ltd., Tokyo, Japan). The pO2 monitoring system has been commonly used in physiologic and 
anesthetic research, and details of this machine have been reported previously (33). An oxygen 
electrode probe of a 200 μm diameter was inserted into tumors of immobilized mice without 
general anesthesia, and then pO2 was measured at least 10 different points in each tumor and 
the mean pO2 was calculated. After the measurement, the tumors were excised and weighed.  
 
 
PET scanning for tumor-bearing mice. Whole-body small-animal PET imaging was 
performed on a micro-PET scanner (Inveon, Siemens Medical Solutions USA, Inc., Knoxville, 
TN). Imaging studies were carried out on BALB/c nude mice (7 weeks old, female) bearing 
subcutaneous SCC-9, U87MG, RAMOS, HT-29 and LL-2 tumors. The mice were injected via 
the tail vein with 10 MBq of 18F-FDG. These mice were fasted for at least 6 h prior to 
administration of 18F-FDG. Just before imaging, mice were anesthetized with pentobarbital, 
placed in the prone position and imaged. Each 10 minute static data sets were collected for 60 
min. 
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FIGURE LEGENDS 
Figure 1. Spectral properties of BTP  
(a) Chemical structure of Ir(btp)2(acac) (BTP) 
(b) Absorption (green line) and phosphorescence (red line) spectra of BTP in 
1,2-dichloroethane at room temperature.  
 
Figure 2. Cell imaging with BTP  
(a) BTP imaging of the three cell lines CHO, HeLa, and U251. The cells were placed at 20% 
O2 (upper panel) and 5% O2 (lower panel).  
(b) HeLa cells were placed at 20%, 10%, 5%, or 2.5% O2 concentration. Upper panel, BTP 
loading. Lower panel, HIF1α immunostaining. 
(c) Western blot of HIF1α. HeLa cell lysates were subjected to SDS-PAGE after incubation 
with 20%, 10%, 5%, or 2.5% O2. 
 
Figure 3. In vivo imaging with BTP. 
(a) Tumor imaging. Tumor-bearing athymic nude mice were injected with 250 nmol BTP/100 
μl DMSO from the tail vein. For BTP imaging, a tumor-bearing mouse was anesthetized by 
injecting pentobarbital (1.0 mg/mouse) intraperitoneally. The tumor image was obtained at 0, 
5 and 60 min after the BTP injection.  
(b) Removal of BTP from the SCC-7 tumor. After BTP injection (250 nmol/mouse), BTP 
image was chased for 48 h. The intensity of BTP image was evaluated by assuming 0 min 
point image intensity as 1.0.  
 
Figure 4. Tumor detection limit of BTP image.  
SCC-7 cells were injected into three nude mice, and tumor size was measured periodically. 
The diameter of the tumor was obtained by subtracting the thickness of skin. For imaging the 
tumor, 250 nmol BTP/100 μl was injected into a tumor-bearing mouse, and tumor image was 
obtained 1 h after the injection. The intensity of BTP image was evaluated by assuming 0 min 
point image intensity as 1.0. Visual limit was plotted by a red broken line, and arrows indicate 
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a visible region. The tumor diameter and intensity of BTP image of the three tumor-bearing 
mice are shown by the three symbols, circle, triangle, and square for each mouse.  
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pO2 (mmHg)
SCC-7 18.3 ±0.8
U87MG 19.4 ±1.7
RAMOS 20.3 ±0.6
HT-29 18.9 ± 0.8
LL-2 19.7 ± 0.6
Table 1  pO2 levels in tumors
Tumor pO2 was measured by a needle-type polarographic
oxygen electrode. The pO2 in each tumor stayed in a narrow
range before and after BTP imaging. Values are the mean ±
SD of at least five independent experiments. 
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